You just read:

US Gastroenterologists May Thwart Uptake of New Biosimilars Such as, Pfizer's Inflectra and Merck/Samsung Bioepis' Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie's Humira

News provided by

Spherix Global Insights

Aug 29, 2017, 04:00 ET